Pregabalin Capsule
Product Images NDC 68788-8391

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-8391). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Capsules 75mg (A0da0534 B386 4c93 Ae89 03b0e3325e02 00)

Label for Pregabalin Capsules 75 mg, generic for Lyrica, in oral capsule form. The label states the active ingredient as 75 mg pregabalin per capsule. It includes storage instructions, manufacturer Ascend Laboratories LLC, and a caution about federal law prohibiting drug transfer. The label also features bilingual dosage direction fields in English and Spanish and branding for Preferred Pharmaceuticals, Inc.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula for calculating creatinine clearance (CLCr) based on age in years, weight in kilograms, and serum creatinine in mg/dL, with a multiplication factor of 0.85 for female patients. This equation is typically used to estimate kidney function.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar graph displaying responder rates (%) from two studies, Study E1 and Study E3, assessing various doses of Pregabalin (oral capsule) versus placebo. The x-axis shows placebo and Pregabalin dosages in mg/day with dosing frequency (BID or TID). The y-axis measures responder rates from 0% to 60%. Data indicates increasing responder rates with higher dosages of Pregabalin compared to placebo.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph depicting seizure reduction as median percent change from baseline versus dose in mg/day for Pregabalin. The graph compares results from three studies (E1 BID, E2 TID, and E3 BID and TID) with dose levels 0 (placebo), 50, 150, 300, and 600 mg/day. Significant p-values are indicated at data points showing dose-dependent seizure reduction.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at 75 mg three times a day, 150 mg three times a day, 300 mg three times a day, and placebo, illustrating patient response to different dosages in terms of pain improvement.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph showing the percent improved of subjects over a range of percent improvement from baseline to week 12 BOCF, comparing Pregabalin and placebo groups. The y-axis represents percent of subjects improved, and the x-axis represents percent improvement from baseline. The graph includes two lines indicating different improvement trends for Pregabalin versus placebo.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percent improvement from baseline to Week 16 on the Horizontal axis (ROCF) against the percent of subjects improved on the Vertical axis. Two lines are shown, one solid representing Pregabalin and one dashed representing Placebo, indicating a higher percentage of subjects improve with Pregabalin compared to Placebo over the range.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph showing the percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. It compares the effects of Pregabalin 100 mg three times a day versus placebo, illustrating patient improvement trends over varying pain improvement percentages.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day against a placebo, showing the trend of patient improvement across increasing pain improvement percentages.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph comparing the percent improvement in pain from baseline on the x-axis with the percent of patients improved on the y-axis. It displays three lines representing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and Placebo, showing the relative efficacy of the treatments over various levels of pain improvement.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, with separate lines for each group.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph comparing the percent improvement in pain from baseline to the percent of patients improved for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg versus placebo. The graph shows trends indicating greater patient improvement with Pregabalin doses compared to placebo across varying levels of pain improvement.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve chart comparing estimated percentage of subjects without LTR (loss to remission) over 180 days. Two lines represent Pregabalin and Placebo groups, showing a higher percentage of subjects without LTR in the Pregabalin group over time.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure diagram of pregabalin showing its molecular framework with components such as amino (NH2) and carboxyl (CO2H) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.